Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23658055 | 1.00 | NR1H2 (0.43) | NR1H2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18637508 | 1.00 | NR1H2 (0.43) | NR1H2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18604596 | 1.00 | NR1H2 (0.43) | NR1H2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL17079738 | 1.00 | NR1H2 (0.43) | NR1H2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL17087656 | 1.00 | NR1H2 (0.43) | NR1H2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18604605 | 0.87 | NR1H2 (0.46) | NR1H2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL17087673 | 0.87 | NR1H2 (0.46) | NR1H2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18604606 | 0.87 | NR1H2 (0.46) | NR1H2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18623977 | 0.87 | NR1H2 (0.46) | NR1H2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25759682 | 0.85 | NR1H2 (0.54) | NR1H2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | NR1H2 1098/4885MEN1 1690/4885KMT2A 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.